No title
Longitudinal assessment of brain atrophy, particularly in the hippocampus, is a well-studied biomarker for neurodegenerative diseases, such as Alzheimer’s disease (AD). Estimating brain progression patterns can be applied to understanding the therapeutic effects of amyloid-clearing drugs in research and detecting the earliest sign of accelerated atrophy in clinical settings. However, most state-of
